Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Pembrolizumab for Advanced Cervical Cancer

Jun 13, 2018, 10:25 AM
URL:
On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck and Co. Inc.) for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.

Read the full FDA press release here.

Posted 6/13/2018

Leave a comment